Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 223

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 223
---
843)Property and equipment, net$10,627 $11,545 Depreciation and amortization expense on property and equipment was approximately $0.5 million and $1.6 million for the three and nine months ended September 30, 2025 and $0.6 million and $1.8 million for the three and nine months ended September 30, 2024, respectively.

Accounts Payable and Accrued LiabilitiesSeptember 30,2025December 31,2024(unaudited)Accounts payable$8,177 $4,587 Accrued compensation, benefits, & related accruals35,297 21,225 Accrued sales & marketing14,838 11,007 Accrued manufacturing expenses13,099 11,652 Accrued R&D expenses9,109 5,898 Operating lease liabilities, current portion(1)10,790 6,889 Accrued royalties(2)3,868 8,105 Other accrued expenses13,435 6,989 Total$108,613 $76,352 _______________________________(1)  Refer to Note 13, Leases.(2)  Refer to Note 17, Commitments and Contingencies.

Accrued Product Returns and RebatesSeptember 30,2025December 31,2024(unaudited)Accrued product rebates$141,190 $115,330 Accrued product returns43,269 53,375 Total$184,459 $168,705 

17.    Commitments and Contingencies

Product LicensesThe Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third parties, computed as a percentage of net product sales, for each respective product under a license agreement.Through the USWM Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for APOKYN, ONAPGO, XADAGO, and MYOBLOC. The Company is obligated to pay royalties to third parties, computed as a percentage of net product sales, for each of the products under the respective license agreements. The royalty expense incurred for these acquired products is recognized as Cost of goods sold in the